1. France Stocks

  2. •

    Health technology

  3. •

    Medical specialties
Safe SA

Safe SA

0.60
EUR
0.00
(0.00%)
358,633.80Market Cap
2013 Y
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
87,909.09
186,636.36
66,631.58
59,625
67,608.7
46,905.41
4,380.26
1,228,000
912,200
80.91
528,181.82
3,687.64
26.92
- -
Basic EPS, GAAP
-290,272.73
-448,727.27
-172,789.47
-150,125
-142,934.78
-78,378.38
-7,285.19
-2,768,666.67
-1,341,800
-96.16
-18,676,727.27
-1,411,355.52
-23.46
- -
Free Cash Flow per Basic Share
-362,090.91
-530,909.09
-184,815.79
-148,500
-107,173.91
-83,986.49
-3,920.48
-2,177,666.67
-1,643,000
-87.35
5,880,636.36
-2,457.94
-10.81
- -
Dividend per Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Book Value per Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
-18,395,818.18
-1,091.22
-53.6
-53.6
Tangible Book Value per Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
-18,396,727.27
-1,110.39
-55.03
-55.03
Basic Weighted Avg Shares
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Sales/Revenue/Turnover
1
2
3
2
3
3
5
4
5
6
6
5
5
- -
Operating Margin (%)
-319.86
-271.12
-285.07
-263.56
-174.73
-177.18
-155.45
-181
-166.21
-102.24
-108.78
-155.62
-65.88
- -
Depreciation Expense
- -
1
1
- -
- -
- -
- -
1
1
1
4
1
- -
- -
Net Income, GAAP
-3
-5
-7
-6
-7
-6
-8
-8
-7
-7
-205
-1,929
-5
- -
Effective Tax Rate (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Profit Margin (%)
-330.2
-240.43
-259.32
-251.78
-211.41
-167.1
-166.32
-225.46
-147.09
-118.84
-3,536.04
-38,272.62
-87.14
- -
Working Capital
- -
2
7
5
5
5
- -
3
-1
-3
-267
-11
-12
-12
LT Debt
1
1
3
6
5
5
6
8
5
5
3
1
1
1
Total Equity
- -
2
5
- -
1
1
-4
- -
- -
-1
-202
-8
-11
-11
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Common Equity (%)
- -
- -
-173.84
-220
-922.81
-515.33
- -
- -
-2,113.07
- -
- -
- -
- -
- -

Capital Structure

EUR

•

in mil. unless spec.
Dec'24
Jun'25
Dec'25
ST Debt
11
14
13
LT Borrowings
- -
- -
- -
LT Finance Leases
1
1
1
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
- -
- -
- -
Market Capitalization
13,892,400
- -
- -

Working Capital

EUR

•

in mil. unless spec.
Dec'24
Jun'25
Dec'25
Total Current Assets
7
4
8
Cash, Cash Equivalents & STI
- -
- -
- -
Accounts Receivable, Net
3
1
4
Inventories
3
3
3
Total Current Liabilities
18
22
21
Payables & Accruals
- -
- -
- -
ST Debt
11
14
13
Deferred Revenue
- -
- -
- -

Growth Rates

EUR

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
1,484.27%
3,059.76%
26.81%
Free Cash Flow
-124.58%
-252.15%
-35.92%
Net Income, GAAP
360.44%
714.72%
-99.76%
Sales/Revenue/Turnover
9.57%
8.92%
6.41%
Total Cash Common Dividend
- -
- -
- -

Semi-annual Revenue

EUR

•

in mil. unless spec.

Year

H1
H2
FY
2023
- -
- -
6
2024
- -
- -
5
2025
- -
- -
5

Semi-annual Earnings Per Share

EUR

•

in mil. unless spec.

Year

H1
H2
FY
2023
- -
- -
-18,676,727.27
2024
- -
- -
-1,411,355.52
2025
- -
- -
-23.46

Semi-annual Dividends Per Share

EUR

•

in mil. unless spec.

Year

H1
H2
FY
2023
- -
- -
- -
2024
- -
- -
- -
2025
- -
- -
- -

Company Description

Company Profile APIChatGPT
CEO
Nicolas Papillon
Full Time Employees
90
Sector
Health technology
Industry
Medical specialties
Address
Parc des Bellevues Fleurieux-sur-L’Arbresle France 95610
IPO Date
Feb 10, 2015
Website
safeorthopaedics.com
Similar Companies
Intuitive Surgical, Inc. (NASDAQ:ISRG)
Boston Scientific Corporation (NYSE:BSX)
Thermo Fisher Scientific Inc (NYSE:TMO)
Illumina, Inc. (NASDAQ:ILMN)
Abbott Laboratories (NYSE:ABT)
GRAIL, Inc. (NASDAQ:GRAL)
Business
Safe Orthopaedics S.A., a medical technology enterprise, focuses on the conception, manufacturing, and commercialization of specialized sterile implants paired with single-use instruments for spine surgery across France and various international markets. The company's innovative portfolio addresses both spinal trauma and degenerative conditions. Key offerings include the SteriSpine PS system, a comprehensive solution for fracture reduction and stabilization featuring Cypress implants and the Oak screw for minimally invasive approaches. Additionally, Safe Orthopaedics provides the SteriSpine LC lumbar cage system, encompassing designs like Cedar and Elm, and the SteriSpine CC cervical cage platform, which includes products such as Walnut. Their SteriSpine VA product line delivers ready-to-use kyphoplasty and cement solutions. The firm distinguishes itself with ready-to-use technologies that streamline surgical procedures, potentially reducing operating room logistics by 80%, lowering infection risks by up to 66%, and offering significant cost savings for hospitals. Founded in 2010, the company recently emerged from court-ordered receivership in November 2024, embarking on a new strategic direction and relocating its headquarters to Fleurieux-sur-l'Arbresle, France. It is also moving towards forming the "Up Group" to integrate its operations with Safe Medical and SpineUp.